Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 07, 2025, titled "Zydus announces agreement with CVS Caremark to add Zituvio TM, Zituvimet TM and Zituvimet TM XR (Sitagliptin Sitagliptin and Metformin Hydrochloride) to its template formulary".
Press Release Jan 07 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a new agreement with CVS Caremark to include its products Zituvio, Zituvimet, and Zituvimet XR in CVS's template formulary. This partnership aims to enhance patient access to these diabetes medications, which have been approved by the USFDA. The press release emphasizes Zydus's commitment to improving healthcare access and its strategic investments in innovative products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 19 2024
- Press Release Nov 12 2024
- Press Release Oct 23 2024
- Press Release Oct 17 2024
- Press Release Oct 14 2024
Later from Zydus Lifesciences
- Press Release Jan 18 2025
- Press Release Jan 22 2025
- Press Release Jan 26 2025
- Press Release Jan 30 2025
- Press Release Feb 05 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences